PL1838716T3 - Dihydrat embonianu olanzapiny - Google Patents

Dihydrat embonianu olanzapiny

Info

Publication number
PL1838716T3
PL1838716T3 PL05855335T PL05855335T PL1838716T3 PL 1838716 T3 PL1838716 T3 PL 1838716T3 PL 05855335 T PL05855335 T PL 05855335T PL 05855335 T PL05855335 T PL 05855335T PL 1838716 T3 PL1838716 T3 PL 1838716T3
Authority
PL
Poland
Prior art keywords
olanzapine pamoate
pamoate dihydrate
dihydrate
olanzapine
schizophrenia
Prior art date
Application number
PL05855335T
Other languages
English (en)
Inventor
Julie Kay Bush
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36024754&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1838716(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL1838716T3 publication Critical patent/PL1838716T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05855335T 2005-01-05 2005-12-22 Dihydrat embonianu olanzapiny PL1838716T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64169305P 2005-01-05 2005-01-05
EP05855335A EP1838716B1 (en) 2005-01-05 2005-12-22 Olanzapine pamoate dihydrate
PCT/US2005/046752 WO2006073886A1 (en) 2005-01-05 2005-12-22 Olanzapine pamoate dihydrate

Publications (1)

Publication Number Publication Date
PL1838716T3 true PL1838716T3 (pl) 2011-09-30

Family

ID=36024754

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05855335T PL1838716T3 (pl) 2005-01-05 2005-12-22 Dihydrat embonianu olanzapiny

Country Status (11)

Country Link
US (1) US7932249B2 (pl)
EP (1) EP1838716B1 (pl)
JP (1) JP4940152B2 (pl)
AT (1) ATE511512T1 (pl)
CY (1) CY1111762T1 (pl)
DK (1) DK1838716T3 (pl)
ES (1) ES2363364T3 (pl)
PL (1) PL1838716T3 (pl)
PT (1) PT1838716E (pl)
SI (1) SI1838716T1 (pl)
WO (1) WO2006073886A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
SI1838716T1 (sl) 2005-01-05 2011-10-28 Lilly Co Eli Olanzapin pamoat dihidrat
WO2011091142A2 (en) * 2010-01-20 2011-07-28 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of olanzapine pamoate
US9132136B2 (en) * 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
EP2629775A4 (en) 2010-10-18 2014-06-11 Dainippon Sumitomo Pharma Co INJECTABLE FORMULATION WITH DELAYED RELEASE
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
BR112020013750A8 (pt) 2018-01-05 2022-10-18 Impel Neuropharma Inc Dispensação intranasal de olanzapina por dispositivo olfativo de precisão
TWI756536B (zh) * 2019-04-12 2022-03-01 佳勝科技股份有限公司 改質液晶高分子的製作方法、液晶高分子組合物及改變液晶高分子之熔點的方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3354036A (en) 1963-11-19 1967-11-21 Du Pont Method of producing depression
GB1343936A (en) 1970-07-21 1974-01-16 Endo Lab Narcotic antagonist compositions having prolonged activity
US3676557A (en) 1971-03-02 1972-07-11 Endo Lab Long-acting narcotic antagonist formulations
ES410734A1 (es) 1973-01-18 1976-01-01 Rocador Sa Procedimiento para la obtencion del pamoato de butacaina.
US3895111A (en) 1973-06-27 1975-07-15 American Cyanamid Co Asthma treatment by inhalation of micronized N,N-diethyl-4-methyl-1-piperazinecarboxamide pamoate
US4016273A (en) 1975-07-16 1977-04-05 American Cyanamid Company Sustained release forms of certain oxazepines for parenteral administration
US4076942A (en) 1975-10-01 1978-02-28 Merck & Co., Inc. Crystalline dipilocarpinium pamoate
GB1539277A (en) 1977-09-16 1979-01-31 Wyeth John & Brother Ltd Hexahydro-1h-azepines
US4320124A (en) 1980-10-17 1982-03-16 Pfizer Inc. Composition for enhancing binding of a benzodiazepine to central benzodiazepine receptors and use thereof
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
DE3324192A1 (de) 1983-07-05 1985-01-17 Troponwerke Gmbh & Co Kg Depot-antiphlogistika
US4816247A (en) 1985-09-11 1989-03-28 American Cyanamid Company Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs
US4784845A (en) 1985-09-16 1988-11-15 American Cyanamid Company Emulsion compostions for the parenteral administration of sparingly water soluble ionizable hydrophobic drugs
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5292760A (en) 1987-12-07 1994-03-08 Hoechst-Roussel Pharmaceuticals Inc. 4-heteroaryl-1,3-benzodiazepines and 2-substituted-α-(heteroaryl)benzeneethanamines
JPH01284333A (ja) 1988-05-11 1989-11-15 T Hasegawa Co Ltd 乳化液組成物
GB8819059D0 (en) 1988-08-11 1988-09-14 Lilly Industries Ltd Benzodiazepine compounds & their use as pharmaceuticals
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5439688A (en) 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
GB9009229D0 (en) 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
FR2663224B1 (fr) 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
US5605897A (en) 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
EP0569096A1 (en) 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation
DE69327542T2 (de) 1992-11-17 2000-07-06 Yoshitomi Pharmaceutical Industries, Ltd. Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
CA2178592C (en) 1993-12-09 2009-07-28 Zentaris Gmbh Long-acting injection suspensions and a process for their preparation
JP3701693B2 (ja) 1993-12-28 2005-10-05 日本製薬株式会社 鎮痛薬含有注射用徐放性脂肪乳剤
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
EG24221A (en) 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5776928A (en) 1995-04-21 1998-07-07 Eli Lilly And Company Method for treating dyskinesias with olanzapine
JPH11506096A (ja) 1995-05-30 1999-06-02 イーライ・リリー・アンド・カンパニー 認識機能不全を処置する方法
AU5872596A (en) 1995-06-01 1996-12-18 Eli Lilly And Company Method for treating anorexia
US5693336A (en) 1995-06-07 1997-12-02 Nexstar Pharmaceuticals, Inc. Blood stable liposomal cyclosporin formulations
US5891461A (en) 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
JPH09157159A (ja) 1995-12-11 1997-06-17 Lion Corp カロチノイド含有組成物
JP2001500878A (ja) 1996-09-23 2001-01-23 イーライ・リリー・アンド・カンパニー オランザピン二水和物ｄ
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6169084B1 (en) * 1997-09-30 2001-01-02 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
HK1041199B (en) * 1998-09-30 2005-03-18 Eli Lilly & Company 2-Methyl-thiophenone-benzodiazine formula
SK2502003A3 (en) * 2000-08-31 2004-03-02 Reddys Lab Ltd Dr Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
CA2464306A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
SI1838716T1 (sl) 2005-01-05 2011-10-28 Lilly Co Eli Olanzapin pamoat dihidrat

Also Published As

Publication number Publication date
EP1838716B1 (en) 2011-06-01
EP1838716A1 (en) 2007-10-03
PT1838716E (pt) 2011-07-15
ES2363364T3 (es) 2011-08-02
JP2008526748A (ja) 2008-07-24
CY1111762T1 (el) 2015-10-07
SI1838716T1 (sl) 2011-10-28
US20080096871A1 (en) 2008-04-24
JP4940152B2 (ja) 2012-05-30
ATE511512T1 (de) 2011-06-15
DK1838716T3 (da) 2011-07-25
WO2006073886A1 (en) 2006-07-13
US7932249B2 (en) 2011-04-26

Similar Documents

Publication Publication Date Title
CL2007003155A1 (es) Compuestos derivados de 3,7-diazabiciclo[3.3.0]octano o 3,7-diazabiciclo[3.3.1]nonano, moduladores de receptores nicotinicos neuronales; composicion farmaceutica; y uso en el tratamiento de trastornos del snc.
PT2383271E (pt) Aminoquinolonas como inibidores de gsk-3
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
WO2009009173A3 (en) Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
GB2414933B (en) Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
EP2023926A4 (en) PYRIDONECARBOXAMIDE DERIVATIVES USEFUL FOR TREATING HYPERPROLIFERATIVE AND ANGIOGENESIS RELATED DISORDERS
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
PL1984357T3 (pl) Związki 2,4-pirymidynodiaminy do leczenia lub zapobiegania chorób autoimmunologicznych
MY173616A (en) Compositions and methods for lowering triglycerides
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
IL182180A0 (en) 2h-1,3-benzoxazin-4(3h)-one derivatives and pharmaceutical compositions containing the same
WO2008127364A3 (en) Antiviral compounds and use thereof
CA2645871A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OXALATE-ASSOCIATED DISEASE
TW200800967A (en) Benzimidazole thiophene compounds
CL2007002757A1 (es) Compuestos derivados de 1,2,4-triazina sustituida; composicion farmaceutica; y uso en el tratamiento o prevencion del reflujo gastroesofagico y ansiedad.
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
IL186217A0 (en) Anti-inflammatory modalities
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
IL186102A0 (en) Alpha ketoamide derivatives and pharmaceutical compositions containing the same
WO2007144057A3 (en) Antimicrobial carbon